This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

OMass Therapeutics Raises $100m in Series B to Progress Drug Pipeline

OMass Therapeutics Raises $100m in Series B to Progress Drug Pipeline

28 Apr 2022

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi Ventures, with existing investors, Syncona, Oxford Science Enterprises, and Oxford University also participating Investment will advance OMass’s portfolio of novel drugs against highly-validated, yet intractable or inadequately drugged, membrane- and... Read more

Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Office

Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Office

05 Apr 2022

OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia’s drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific... Read more

Genomics England expands use of Oxford Nanopore sequencing in cancer

Genomics England expands use of Oxford Nanopore sequencing in cancer

04 Apr 2022

Oxford Nanopore technology will be used by Genomics England to investigate and validate at increasing scale the benefits of sequencing for improving patient care and advancing research to develop new treatments. Genomics England’s “Long-Read Sequencing Programme” takes advantage of Oxford Nanopore’s ability to sequence any-length fragments of DNA, including long and ultra-long Oxford Nanopore has announced today the next steps in its... Read more

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon

21 Mar 2022

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon    Chairing the Clinical Advisory Group to guide clinical development strategy Oxford, UK, March 21 2022 – OrthoSon, which is developing minimally invasive and motion-restoring treatments for low back pain based on ultrasound and in-situ curing hydrogel implants, is pleased to announce the appointment of spine consultant Mr Nick Birch FRCS (Orth) to its Board... Read more

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA

16 Mar 2022

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA Could Be Only Authorized SALIVA Rapid Test; Preferred to Nasal swabs by 4x in user testing OTC Self-Test Detects Virus Via ACE-2 Protein Binding to Trimeric Spike with Mouth Swab MARCH 16, 2022 – Vatic Health Limited (https://www.vatic.health/usa) today announces that it has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA)... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More